- Home
- SGMT vs SLS Comparison
SGMT vs SLS Comparison
Compare SGMT & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGMT
- SLS
- Stock Information
- Founded
- SGMT 2006
- SLS 2012
- Country
- SGMT United States
- SLS United States
- Employees
- SGMT N/A
- SLS N/A
- Industry
- SGMT
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- SGMT
- SLS Health Care
- Exchange
- SGMT Nasdaq
- SLS Nasdaq
- Market Cap
- SGMT 238.7M
- SLS 208.0M
- IPO Year
- SGMT 2023
- SLS N/A
- Fundamental
- Price
- SGMT $7.39
- SLS $1.48
- Analyst Decision
- SGMT Strong Buy
- SLS Strong Buy
- Analyst Count
- SGMT 8
- SLS 1
- Target Price
- SGMT $29.75
- SLS $7.00
- AVG Volume (30 Days)
- SGMT 570.9K
- SLS 3.9M
- Earning Date
- SGMT 11-13-2025
- SLS 11-12-2025
- Dividend Yield
- SGMT N/A
- SLS N/A
- EPS Growth
- SGMT N/A
- SLS N/A
- EPS
- SGMT N/A
- SLS N/A
- Revenue
- SGMT N/A
- SLS N/A
- Revenue This Year
- SGMT N/A
- SLS N/A
- Revenue Next Year
- SGMT N/A
- SLS N/A
- P/E Ratio
- SGMT N/A
- SLS N/A
- Revenue Growth
- SGMT N/A
- SLS N/A
- 52 Week Low
- SGMT $1.73
- SLS $0.77
- 52 Week High
- SGMT $11.41
- SLS $2.48
- Technical
- Relative Strength Index (RSI)
- SGMT 44.02
- SLS 38.23
- Support Level
- SGMT $7.21
- SLS $1.39
- Resistance Level
- SGMT $8.84
- SLS $1.65
- Average True Range (ATR)
- SGMT 0.62
- SLS 0.11
- MACD
- SGMT -0.09
- SLS -0.02
- Stochastic Oscillator
- SGMT 19.69
- SLS 16.38
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.